falsefalse

CROWN and BRIGHTSTAR Studies: Latest Data Insights

, , ,

Peer Exchange | <b>Latest Advances in ALK-Positive and BRAF-Positive V600E NSCLC: Efficacy Updates, Brain Metastases Management, and Optimal Treatment Sequencing </b>

Panelists discuss the key findings from the latest data from the CROWN and BRIGHTSTAR studies, emphasizing efficacy end points and comparing the effectiveness of these regimens with that of others in the treatment landscape for ALK-positive NSCLC.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    1. Dr Bestvina: Please discuss the key findings from the latest data for the CROWN/BRIGHTSTAR studies.
    • CROWN
    • Please specifically discuss and emphasize efficacy end points here. How does the efficacy of this regimen compare with that of others in this space?
    • BRIGHTSTAR

    Related Content:

    Leveraging ctDNA Platforms in High-Risk Patients: Current Applications and Future Potential
    Translating Metastatic Insights to Early-Stage Management: Current Practices and Future Direction
    EGFR Therapy Evolution: Resistance Mechanisms, Combination Strategies, and Advanced Testing
    x